PLATINUM-RESISTANT RECURRENT OVARIAN CANCER (PROC)
Clinical trials for PLATINUM-RESISTANT RECURRENT OVARIAN CANCER (PROC) explained in plain language.
Never miss a new study
Get alerted when new PLATINUM-RESISTANT RECURRENT OVARIAN CANCER (PROC) trials appear
Sign up with your email to follow new studies for PLATINUM-RESISTANT RECURRENT OVARIAN CANCER (PROC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug WSK-IM02 takes on Hard-to-Treat ovarian cancer
Disease control Not yet recruitingThis early-phase trial is testing an experimental drug called WSK-IM02 in 36 women with platinum-resistant recurrent ovarian cancer, a type that no longer responds to standard platinum chemotherapy. The drug is given as an injection into the abdomen. The main goal is to check saf…
Matched conditions: PLATINUM-RESISTANT RECURRENT OVARIAN CANCER (PROC)
Phase: PHASE1 • Sponsor: WestVac Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for hard-to-treat ovarian cancer: drug duo shows promise in early trial
Disease control Not yet recruitingThis study tests a combination of two drugs (sacituzumab tirumotecan and bevacizumab) in 30 women with platinum-resistant recurrent ovarian cancer, a type that is very hard to treat. The goal is to see if the combo can shrink tumors better than current options. Participants must …
Matched conditions: PLATINUM-RESISTANT RECURRENT OVARIAN CANCER (PROC)
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Zhengzhou University • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC